Iranian Journal of Neurology 2017. 16(3):.

Recurrent isolated optic neuritis: A study on 22 patients
Mahsa Arzani, Mohammad Ali Sahraian, Hamed Rezaei, Abdorreza Naser-Moghadasi

Abstract


Background: Isolated relapsing optic neuropathy is a recurrent painful optic nerve inflammation without any sign of other demyelinating diseases such as multiple sclerosis (MS) or neuromyelitis optica (NMO) spectrum disorders, and the attacks are purely responsive to steroid therapy.

Methods: Recurrent isolated optic neuritis (RION) was diagnosed in patients who presented with at least two disseminating episodes of optic neuritis, and negative clinical, para-clinical, and radiological features of the demyelinating, infiltrative and vasculitis disorders involving optic nerve. The patients were assigned into two groups, chronic recurrent isolated optic neuritis (CRION) entailing patients with steroid dependent attack of optic neuritis and RION patients without steroid dependent attack of optic neuritis. They were monitored over a median of 4.0 ± 2.5 years.

Results: There were 16 women and six men with CRION and RION; with the median age of 31.7 ± 9.8 (29.3 ± 9.7 for women and 37.7 ± 7.7 for men). The women to men ratio was 2.6:1. The mean optic neuritis attack was 2.95 ± 1.32 in total. Eight patients were RION while 14 patients fulfilled CRION criteria and took long term immuno-suppressive drugs. In their follow-up, 4 out of 14 CRION cases (28.5%) showed clinical and concordant para-clinical features of NMO spectrum disorder. The analysis of demographic data showed that the average number of ON attacks in CRION patients (3.79 ± 2.32) was significantly more than the average in patients with RION (2.25 ± 0.46, P = 0.02).

Conclusion: CRION is a disease which requires aggressive glucocorticoid and long-term immunosuppressive therapy to restore visual acuity.

Keywords


Chronic Recurrent Isolated Optic Neuritis; Recurrent Optic Neuritis; Neuromyelitis Optica Spectrum Disorder; Multiple Sclerosis

Full Text:

PDF

References


Arndt C, Labauge P, Speeg-Schatz C, Jeanjean L, Fleury M, Castelnovo G, et al. [Recurrent inflammatory optic neuropathy]. Journal francais d'ophtalmologie. 2008;31(4):363-7.

Petzold A, Plant GT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmunity reviews. 2014;13(4-5):539-45.

Palmi-Cortes I M-LV, Canneti B, Valenzuela-Rojas FJ, Vivancos J Recurrent optic neuritis: the importance of the differential diagnosis. MultScler. 2012:215.

Perez-Diaz H, Casado JL, Ucles-Sanchez A, Saiz A. [Chronic relapsing inflammatory optic neuropathy (CRION) without detection of IgG-NMO antibodies]. Neurologia. 2007;22(8):553-5.

Saini M, Khurana D. Chronic relapsing inflammatory optic neuropathy. Annals of Indian Academy of Neurology. 2010;13(1):61-3.

Kaut O, Klockgether T. 51-year-old female with steroid-responsive optic neuropathy: a new case of chronic relapsing inflammatory optic neuropathy (CRION). Journal of neurology. 2008;255(9):1419-20.

Samra A, Ramtahal J. Recurrent subacute visual loss presenting in a 52-year-old Caucasian woman with chronic relapsing inflammatory optic neuropathy: a case report. Journal of medical case reports. 2012;6:15.

Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain : a journal of neurology. 2003;126(Pt 2):276-84.

Asli Kurne RK, Gul Yalcin-Cakmakli, et al. Recurrent optic neuritis: clues from a long-term follow-up study of recurrent and bilateral optic neuritis patients. . Eye Brain. 2010;2:15-20.

Kurz D, Egan RA, Rosenbaum JT. Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin. American journal of ophthalmology. 2005;140(6):1132-3.

Myers TD, Smith JR, Wertheim MS, Egan RA, Shults WT, Rosenbaum JT. Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. The British journal of ophthalmology. 2004;88(5):673-80.

De Benito L MoL, Martı´nez M, Corte´s C, De Andre´s C. Recurrent bilateral inflammatory idiopathic optic neu- ropathy treated with mycophenolatemofetil: clinical and radio- logical course. Neuroophthalmology 2005;29(4):149-59.

Plant GT, Sibtain NA, Thomas D. Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Multiple sclerosis international. 2011;2011:815068.

Stiebel-Kalish H, Hammel N, van Everdingen J, Huna-Baron R, Lee AG. Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2010;45(1):71-5.

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-200.

Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. Journal of neurology, neurosurgery, and psychiatry. 2010;81(1):109-11.

Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the neurological sciences. 2010;298(1-2):158-62.

Unsold R. [Neuropathies of the optic nerve in inflammatory systemic diseases and vasculitis. A frequently misdiagnosed early symptom]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 1994;91(2):251-62.

Abstracts of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. October 10-13, 2012. Lyon, France. Multiple sclerosis. 2012;18(4 Suppl):9-542.

Falcao B BD, Oliveira EML, GAA NMO, CRION or MS: what we say when we have recurrent optic neuritis. MultScler. 2012;604.

Wiryasaputra S LS. Relationship between Visual Acuity, Visual Field and Retinal Nerve Fibre Layer

Thickness in Optic Neuritis. INOS. 46.

Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. Journal of neurology. 2014;261(1):17-26.

Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in Iran. European neurology. 2014;72(5-6):370-4.

Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2010;17(6):794-9.

Martinez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gomez M, Conesa A, Lozano-Rubi R, et al. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. Journal of neurology. 2014;261(4):759-67.

Benoilid A, Tilikete C, Collongues N, Arndt C, Vighetto A, Vignal C, et al. Relapsing optic neuritis: a multicentre study of 62 patients. Multiple sclerosis. 2013.

Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta ophthalmologica. 2009;87(2):204-10.

Frohman L, Dellatorre K, Turbin R, Bielory L. Clinical characteristics, diagnostic criteria and therapeutic outcomes in autoimmune optic neuropathy. The British journal of ophthalmology. 2009;93(12):1660-6.

Sharma A, Khurana D, Kesav P. MRI findings in chronic relapsing inflammatory optic neuropathy. BMJ case reports. 2013;2013.

Pandit L, Shetty R, Misri Z, Bhat S, Amin H, Pai V, et al. Optic neuritis: experience from a south Indian demyelinating disease registry. Neurology India. 2012;60(5):470-5.

Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Archives of neurology. 2004;61(9):1401-5.

Waschbisch A, Atiya M, Schaub C, Derfuss T, Schwab S, Lee DH, et al. Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity. Journal of the neurological sciences. 2013;331(1-2):72-5.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.